Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 12, 2026
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohortI-Wei Ho, Chung-Pin Li, Shih-Hung Yang, et al.
American Journal of Cancer Research|December 12, 2022
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinomaNai-Jung Chiang, Yan-Shen Shan, Chung-Pin Li, et al.
Eclinicalmedicine|March 27, 2023
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialTanios Bekaii-Saab, Takuji Okusaka, David Goldstein, et al.
British Journal of Cancer|May 30, 2018
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH studyIan Chau, Joon Oh Park, Baek-Yeol Ryoo, et al.
American Journal of Cancer Research|October 13, 2022
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorinYen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 2, 2024
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancerCheng-Yu Tang, Shih-Hung Yang, Chung-Pin Li, et al.
American Journal of Cancer Research|May 9, 2022
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecanShih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, et al.
Theranostics|January 7, 2020
Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2Hsiao-Yun Chen, Mong-Lien Wang, Benoit Laurent, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trialLi-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Lancet (London, England)|November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialAndrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
Pageof 16